Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection - a review of currently available results

J. Vysloužil, K. Kubová, VN. Tkadlečková, D. Vetchý,

. 2019 ; 69 (3) : 297-319. [pub] 2019Sep01

Jazyk angličtina Země Chorvatsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044707

The original purpose of vaginally applied microbicides was to slow down the HIV epidemic among the population until an effective vaccination was developed. Nowadays, antiretrovirals applied in the form of gels or vaginal rings are considered most prominent in this field and are tested via vaginal or, rarely, rectal applications in numerous clinical studies (9 different antiretroviral drugs in 33 clinical studies, especially in Africa). Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) progressed into the phase III clinical testing. Their efficiency depended on the user´s strict adherence to the application regimen (for tenofovir 54 %, for dapivirine 61 % in participants over 25 years of age). Despite this, they are expected to be important and effective tools of preventive medicine in the near future. This review summarizes the results obtained during long-term clinical testing (2005-2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044707
003      
CZ-PrNML
005      
20200113081218.0
007      
ta
008      
200109s2019 ci f 000 0|eng||
009      
AR
024    7_
$a 10.2478/acph-2019-0030 $2 doi
035    __
$a (PubMed)31259738
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ci
100    1_
$a Vysloužil, Jakub $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
245    10
$a Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection - a review of currently available results / $c J. Vysloužil, K. Kubová, VN. Tkadlečková, D. Vetchý,
520    9_
$a The original purpose of vaginally applied microbicides was to slow down the HIV epidemic among the population until an effective vaccination was developed. Nowadays, antiretrovirals applied in the form of gels or vaginal rings are considered most prominent in this field and are tested via vaginal or, rarely, rectal applications in numerous clinical studies (9 different antiretroviral drugs in 33 clinical studies, especially in Africa). Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) progressed into the phase III clinical testing. Their efficiency depended on the user´s strict adherence to the application regimen (for tenofovir 54 %, for dapivirine 61 % in participants over 25 years of age). Despite this, they are expected to be important and effective tools of preventive medicine in the near future. This review summarizes the results obtained during long-term clinical testing (2005-2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.
650    _2
$a antiretrovirové látky $x terapeutické užití $7 D044966
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a antikoncepční prostředky ženské $x virologie $7 D003274
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x farmakoterapie $7 D015658
650    _2
$a lidé $7 D006801
650    _2
$a rektum $x virologie $7 D012007
650    _2
$a vagina $x virologie $7 D014621
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kubová, Kateřina $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Tkadlečková, Veronika Nováková $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
700    1_
$a Vetchý, David $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
773    0_
$w MED00000116 $t Acta pharmaceutica (Zagreb, Croatia) $x 1846-9558 $g Roč. 69, č. 3 (2019), s. 297-319
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31259738 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113081550 $b ABA008
999    __
$a ok $b bmc $g 1482976 $s 1083380
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 69 $c 3 $d 297-319 $e 2019Sep01 $i 1846-9558 $m Acta pharmaceutica $n Acta Pharm $x MED00000116
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...